HILDEN, Germany, and GERMANTOWN, Md.--(BUSINESS WIRE)--Aug 1, 2018--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its care HPV™ Test, one of the only molecular diagnostics for high-risk human papillomavirus (HPV) designed to screen women in low-resource settings, has been added to the World Health Organization (WHO) list of prequalified in vitro diagnostics (IVDs). HPV is the primary cause of cervical cancer, so screening women for the presence of the virus is a critical aspect for prevention and early treatment of the deadly cancer. The  care HPV Test was launched globally in 2010 and through numerous pilot studies has demonstrated to be a more sensitive alternative to cytology and visual inspection based methods for the detection of pre-cancerous cell abnormalities. The WHO’s evidence-based listing is expected to expand the availability of this critical diagnostic tool in countries that rely on the global organization’s list in making purchasing decisions. The WHO Prequalification status will significantly broaden access to HPV DNA testing to areas of the world with a high burden of cervical cancer.

“The WHO prequalified IVD listing is a ‘stamp of approval’ for our innovative care HPV Test, and this will encourage authorities to adopt efficient, highly accurate HPV screening for prevention of cervical cancer in settings with limited healthcare infrastructure,” said Thierry Bernard, Senior Vice President, Molecular Diagnostics Business Area, for QIAGEN. “China routinely uses care HPV in rural or low-resource areas, and QIAGEN partners with non-governmental organizations and health ministries in developing countries. We expect the WHO listing to drive further dissemination of this important tool for women’s health.”

Please find the full press release here

View source version on businesswire.com:https://www.businesswire.com/news/home/20180801005085/en/

CONTACT: Investor Relations

John Gilardi

+49 2103 29 11711

or

Dr. Sarah Fakih

+49 2103 29 11457

e-mail:ir@QIAGEN.com

or

Public Relations

Dr. Thomas Theuringer

+49 2103 29 11826

or

Robert Reitze

+49 2103 29 11676

e-mail:pr@QIAGEN.com

KEYWORD: AUSTRIA UNITED STATES EUROPE NORTH AMERICA MARYLAND GERMANY SWITZERLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES ONCOLOGY

SOURCE: QIAGEN N.V.

Copyright Business Wire 2018.

PUB: 08/01/2018 03:00 AM/DISC: 08/01/2018 03:00 AM

http://www.businesswire.com/news/home/20180801005085/en